Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Queensland Health
Medtronic
Express Scripts
Cerilliant
Accenture
Chinese Patent Office
Fish and Richardson

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOLODYN

« Back to Dashboard

Clinical Trials for Solodyn

Trial ID Title Status Sponsor Phase Summary
NCT01048983 Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) Withdrawn National Cancer Institute (NCI) Phase 1/Phase 2 The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
NCT01048983 Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) Withdrawn M.D. Anderson Cancer Center Phase 1/Phase 2 The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
NCT01173692 Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. Active, not recruiting National Cancer Institute (NCI) Phase 2 The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.
NCT01173692 Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. Active, not recruiting M.D. Anderson Cancer Center Phase 2 The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.
NCT01206348 Combination Treatment for Moderate to Severe Acne Completed Medicis Global Service Corporation Phase 4 To determine if a combination of three currently approved acne products are safe and effective for the treatment of moderate to severe acne
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Solodyn

Condition Name

Condition Name for Solodyn
Intervention Trials
Lung Cancer 2
Head And Neck Cancer 2
Myeloma 2
Back Pain Without Radiation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Solodyn
Intervention Trials
Carcinoma, Non-Small-Cell Lung 3
Lung Neoplasms 3
Neoplasms, Plasma Cell 2
Multiple Myeloma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Solodyn

Trials by Country

Trials by Country for Solodyn
Location Trials
United States 28
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Solodyn
Location Trials
Texas 11
North Carolina 2
Michigan 2
Alabama 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Solodyn

Clinical Trial Phase

Clinical Trial Phase for Solodyn
Clinical Trial Phase Trials
Phase 4 1
Phase 2 11
Phase 1/Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Solodyn
Clinical Trial Phase Trials
Active, not recruiting 7
Recruiting 3
Completed 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Solodyn

Sponsor Name

Sponsor Name for Solodyn
Sponsor Trials
M.D. Anderson Cancer Center 11
National Cancer Institute (NCI) 10
University of Texas Southwestern Medical Center 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Solodyn
Sponsor Trials
Other 23
NIH 11
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Deloitte
Accenture
Harvard Business School
AstraZeneca
McKesson
Johnson and Johnson
UBS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.